Press Releases Press Releases Year: - Any -20202019201820172016201520142013 June 24, 2020 Summary ToggleMelinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase June 09, 2020 Summary ToggleMelinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals April 20, 2020 Summary ToggleMelinta Therapeutics Successfully Completes Financial Restructuring March 04, 2020 Summary ToggleMelinta Therapeutics Confirms Deerfield as Successful Bidder for Company February 13, 2020 Summary ToggleMelinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures December 27, 2019 Summary ToggleMelinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility November 12, 2019 Summary ToggleMelinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019 October 24, 2019 Summary ToggleMelinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) September 03, 2019 Summary ToggleMelinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director August 09, 2019 Summary ToggleMelinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
Press Releases Year: - Any -20202019201820172016201520142013 June 24, 2020 Summary ToggleMelinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase June 09, 2020 Summary ToggleMelinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals April 20, 2020 Summary ToggleMelinta Therapeutics Successfully Completes Financial Restructuring March 04, 2020 Summary ToggleMelinta Therapeutics Confirms Deerfield as Successful Bidder for Company February 13, 2020 Summary ToggleMelinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures December 27, 2019 Summary ToggleMelinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility November 12, 2019 Summary ToggleMelinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019 October 24, 2019 Summary ToggleMelinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) September 03, 2019 Summary ToggleMelinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director August 09, 2019 Summary ToggleMelinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
